Home Cart Sign in  
Chemical Structure| 285983-48-4 Chemical Structure| 285983-48-4

Structure of Doramapimod
CAS No.: 285983-48-4

Chemical Structure| 285983-48-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Doramapimod is a highly selective p38α MAPK inhibitor with Kd of 0.1 nM, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2, ZAP-70, EGFR, HER2, PKA, PKC, PKCα/β/γ.

Synonyms: BIRB 796

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Doramapimod

CAS No. :285983-48-4
Formula : C31H37N5O3
M.W : 527.66
SMILES Code : O=C(NC1=C2C=CC=CC2=C(OCCN3CCOCC3)C=C1)NC4=CC(C(C)(C)C)=NN4C5=CC=C(C)C=C5
Synonyms :
BIRB 796
MDL No. :MFCD09752957
InChI Key :MVCOAUNKQVWQHZ-UHFFFAOYSA-N
Pubchem ID :156422

Safety of Doramapimod

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Doramapimod

MAPK
TLR

Isoform Comparison

Biological Activity

Target
  • JNK2

  • p38α

    p38α, IC50:38 nM

    p38α, Kd:0.1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
FA-iPSCs 5 μM 1 week Doramapimod significantly improved the derivation of CD34+/CD43+ progenitors from FA-iPSCs, particularly in the CD34hi/CD43lo population. PMC4291073
NK cells 0.05 – 1μM Overnight Restoration of NK cell function and metabolic profile, particularly through p38 inhibition, significantly enhanced TNF-α and CD107a expression and improved mitochondrial function and autophagy capacity PMC9168800
PANC-1 5 µM 24 h To evaluate the effect of Doramapimod on RSL3-induced cell death, results showed that Doramapimod significantly reduced cell death. PMC11447004
BxPC3 5 µM 24 h To evaluate the effect of Doramapimod on RSL3-induced cell death, results showed that Doramapimod significantly reduced cell death. PMC11447004
NP-1 and AF-1 cells 40 nM 6 h Inhibition of p38 kinase, reduction of pRunx2 phosphorylation, and suppression of ADAMTS gene expression PMC10324278
THP-1 macrophages 10 µM 24 h To investigate the inhibitory effect of Doramapimod on p38MAPK phosphorylation, results showed that Doramapimod counteracted the effects of mycobacterial infection and HRH1 on p47phox phosphorylation PMC9600773
MRC-5 human lung fibroblasts 10 µM 72 h Doramapimod inhibited Mtb-induced cell death as effectively as dexamethasone. PMC6368550
J774 mouse macrophages 10 µM 48 h Doramapimod inhibited Mtb-induced cell death as effectively as dexamethasone. PMC6368550
human Mφ isolated from healthy donors 10 µM 48 h Doramapimod inhibited Mtb-induced cell death as effectively as dexamethasone. PMC6368550
human Mφ isolated from treatment naïve TB patients 10 µM 48 h Doramapimod inhibited Mtb-induced cell death as effectively as dexamethasone. PMC6368550
AD293 cells 50 μM 14 h Inhibits SQSTM1 (T269/S272) phosphorylation, reducing aggresome formation PMC9287315
A375 cells 50 μM 14 h Inhibits SQSTM1 (T269/S272) phosphorylation, reducing aggresome formation PMC9287315
MDA-MB-231 cells 50 μM 14 h Inhibits SQSTM1 (T269/S272) phosphorylation, reducing aggresome formation PMC9287315

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NMRInu/nu mice PANC-1 xenograft model oral 50 mg/kg twice weekly until the end of the experiment To evaluate the effect of Doramapimod on gemcitabine treatment, results showed that Doramapimod significantly increased tumor resistance to gemcitabine. PMC11447004
Mice Chronic inflammation model Intraperitoneal injection 4 mg/kg Once a week for 6 weeks Inhibition of p38 kinase, reduction of pRunx2 phosphorylation, and suppression of ADAMTS gene expression, thereby slowing intervertebral disc degeneration PMC10324278
C57BL/6 mice Mtb-infected peritoneal Mφ intraperitoneal injection 100 mg/kg once daily for 3 days Doramapimod significantly protected peritoneal macrophages from Mtb-induced cell death. PMC6368550
Nude mice A375 cell subcutaneous tumor model Oral 10 mg/kg Twice a week for 38 days Doramapimod combined with Bortezomib significantly enhanced antitumor activity, but also accompanied by obvious weight loss PMC9287315

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02208856 Healthy Phase 1 Completed - -
NCT02211170 Healthy Phase 1 Completed - -
NCT02209831 Healthy Phase 1 Completed - -
NCT02209779 Arthritis, Rheumatoid Phase 2 Completed - -
NCT02209792 Crohn Disease Phase 2 Terminated - -
NCT02211157 Healthy Phase 1 Completed - -
NCT02211144 Healthy Phase 1 Completed - -
NCT02209753 Psoriasis Phase 2 Completed - -
NCT02214888 Arthritis, Rheumatoid Phase 2 Terminated - -
NCT02211885 Healthy Phase 1 Completed - -
NCT02209805 Healthy Phase 1 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.48mL

1.90mL

0.95mL

18.95mL

3.79mL

1.90mL

References

 

Historical Records

Categories